Company: MYSEW
Filing Date: 2025-01-08
Form Type: 424B5
Source: 0001213900-25-002125
Chunk: 12

Company: Myseum, Inc.
Filing Date: 2025-01-08
Form: 424B5
Chunk 12
---
 stock issuable upon the exercise of outstanding warrants as of September 30, 2024, at a weighted-average exercise price of $49.80 per share. |

Except as otherwise indicated, all information in this prospectus supplement assumes (i) no exercise of the outstanding options or warrants described above; and (ii) no exercise by the Placement Agent of its warrant to purchase 60,000 shares of common stock.

<div align='center'>S-6

RISK FACTORS</div>

An investment in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks described below, together with other information in this prospectus supplement, the accompanying prospectus and the information and documents incorporated by reference. You should also consider the risks, uncertainties and assumptions discussed under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K and the subsequent reports that we file with the SEC which are on file with the SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. If any of these risks actually occur, our business, financial condition, results of operations or cash flow could be adversely effected. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. Please also read carefully the section below entitled “Special Note Regarding Forward-Looking Statements.”

Risks Related to This Offering and Our Common Stock

Our management team may invest or spend the proceeds raised in this offering in ways with which you may not agree or which may not yield a significant return.

Our management will have broad discretion over the use of proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline, and delay the development of our product candidates.

You will experience substantial dilution.

Based on an offering price
of $4.25 per share, and a net tangible book value of $4.29 million, or approximately $1.42 per share of common stock, as of